

**TFRI GBM 'face to face' Meeting
Delta Chelsea Hotel, Toronto, ON**

7:30 AM – 3:30 PM
Sunday - 28 April 2013

BREAKFAST (7:30am – 8:15am)

Scientific Program – Morning Session

Meeting Chairs – Michael Blough and Gregory Cairncross

1. Introductions (8:15am – 8:20am)
2. Program Overview (8:20am – 8:30am) - Greg Cairncross
3. Tissue Core (8:30am – 8:45am) – Jennifer Chan
 - Overview & Current Status
 - Sub-typing of GBM cases
 - Questions & Discussion
4. BTIC Core (8:45am – 9:30am) – Artee Luchman
 - Overview & Current Status
 - Comparison to expression 'subclasses'
 - Refining culture conditions for IDH cases
 - Experience with 'in vivo' culture
 - Questions & Discussion
5. Stem Cell Marker Core (9:30am – 9:45am) – Sheila Singh
 - Overview & Current Status
 - Drug responses in sorted vs. unsorted cells
 - Questions & Discussion

COFFEE (9:45am – 10:15am)

6. Sequencing Core (10:15am – 11:15am) - Yaoqing Shen
 - Overview & Current Status
 - Early sequencing results - BTICs vs. GBMs
 - Questions & Discussion

7. Medicinal Chemistry Core (11:15am – 11:30pm) – David Uehling OICR
Overview & Current Status
“Drug evaluation cascade”
Questions & Discussion

8. Drug Screening Core, Part 1 (11:30am – 12:00pm) – Natalie Grinshtein
Libraries, BTICs & Strategy
Questions & Discussion

LUNCH (12:00pm – 1:00pm)

Scientific Program – Afternoon Session

9. Drug Screening Core, Part II (1:00pm – 2:00pm) – David Kaplan
Most promising drugs

- Hit from kinase screen (Nathalie)
- Re-purposed drug (Steve Robbins)
- Rigel compound (Sam Weiss)
- Hit from sequencing (Yaoqing)
- Hits from other approaches (David)

Strategies for library expansion
Questions & Discussion

10. Preclinical Core (2:00pm – 3:00pm) – Donna Senger
Overview & Current Status
BTICs selected for *in vivo* screening
Early experience with drugs of interest
Mimicking clinical scenarios *in vivo* (e.g., TMZ/RT)
Experience with *in vitro* / *in vivo* discrepancies
Questions & Discussion

11. Wrap-up and Tasks (3:00pm – 3:30pm)